Fungal respiratory disease

Current Opinion in Pulmonary Medicine

Volumn 12, Issue 3, 2006, Pages 222-227

  Yao, Zhirong ^a   Liao, Wanqing ^b  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Fungal infection; Lung; Respiratory tract

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FUNGAL DNA; VORICONAZOLE; ANTIFUNGAL AGENT;

ASPERGILLOSIS; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LUNG RESECTION; MYCOSIS; NONHUMAN; PATHOGENESIS; PROGNOSIS; RESPIRATORY TRACT INFECTION; REVIEW; SEROLOGY; SURGICAL TECHNIQUE; DIFFERENTIAL DIAGNOSIS; MICROBIOLOGY;

ANTIFUNGAL AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MYCOSES; RESPIRATORY TRACT INFECTIONS;

EID: 33745022629     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000219272.57933.01     Document Type: Review

References (49)

1. Silveira F, Paterson DL. Pulmonary fungal infections. Curr Opin Pulm Med 2005; 11:242-246. This is a review focused on epidemiology, enzyme immunoassay and management of invasive pulmonary aspergillosis.
2. Zander DS. Allergic brochopulmonary aspergillosis. Arch Pathol Lab Med 2005; 129:924-928.
3. Kubak BM. Fungal infection in lung transplantation. Transpl Infect Dis 2002; 4 (suppl 3):24-31.
4. Pagano L, Caira M, Fianchi L. Pulmonary fungal infection with yeasts and pneumocystis in patients with hematological malignancy. Ann Med 2005; 37:259-269.
5. Scott RS, Sutton DA, Jagirdar A. Lung infection due to opportunistic fungus, Phialemonium obovatum, in a bone marrow transplant recipient: an emerging infection with fungemia and Crohn disease-like involvement of the gastrointestinal tract. Ann Diagn Pathol 2005; 9:227-230.
6. Vanittanakom N, Supabandhn J, Khamwan C, et al. Identification of emerging human-pathogenic Pythium insidiosum by serological and molecular assaybased methods. J Clin Microbiol 2004; 42:3970-3974.
7. McLintock LA, Gibson BE, Jones BL. Mixed pulmonary fungal infection with Aspergillus fumigatus and Absidia corymbifera in a patient with relapsed acute myeloid leukaemia. Br J Haematol 2005; 128:737.
8. Sodqi M, Brazille P, Gonzalez-Canali G, et al. Unusual pulmonary Enterocytozoon bieneusi microsporidiosis in an AIDS patient: case report and review. Scand J Infect Dis 2004; 36:230-231.
9. Surmont I, Van Aelst F, Verbanck J, et al. A pulmonary infection caused by Coprinus cinereus (Hormographiella aspergillata) diagnosed after a neutropenic episode. Med Mycol 2002; 40:217-219.
10. Lagrou K, Massonet C, Thennissen K, et al. Fatal pulmonary infection in a leukaemic patient caused by Hormographiella aspergillata. J Med Microbiol 2005; 54:685-688.
11. Buzina W, Lass-Florl C, Kropshofer C, et al. The polypore mushroom Irpex lacteus, a new causative agent of fungal infections. J Clin Microbiol 2005; 43:2009-2011.
12. Sole A, Morant P, Salavert M, et al. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 2005; 11:359-365. Single-institute review of aetiology, clinical presentation, diagnosis and management of invasive aspergillosis in lung-transplant recipients.
13. Tripathy U, Yung GL, Kriett JM, et al. Donor transfer of pulmonary coccidioidomycosis in lung transplantation. Ann Thorac Surg 2002; 73:306-308.
14. Miller MB, Hendren R, Gilligan PH. Posttransplantation disseminated coccidioidomycosis acquired from donor lungs. J Clin Microbiol 2004; 42:2347-2349.
15. Morgan J, Wannemuchler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stemcell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43 (suppl 1):S49-S58. An analysis of causative fungal agents, morbidity and mortality of invasive aspergillosis from 4621 HSCTs and 4110 SOT at 19 sites throughout the USA, over a 22-month period.
16. Muquim A, Dial S, Menzies D. Invasive aspergillosis in patients with chronic obstructive pulmonary diseases. Can Respir J 2005; 12:199-204.
17. Menotti J, Waller J, Meunier O, et al. Epidemiological study of invasive pulmonary aspergillosis in a haematology unit by molecular typing of environmental and patient isolates of Aspergillus fumigatus. J Hosp Infect 2005; 60:61-68. Molecular typing of environmental and patient isolates of A. fumigatus may bring some change to the traditional view. Unfortunately, the sample taken in this study was not large enough.
18. Frezza S, Maggio L, De Carolis MP, et al. Risk factors for pulmonary candidiasis in preterm infants with a birth weight of less than 1250 g. Eur J Pediatr 2005; 164:88-92.
19. Alvarez-Lerma F, Palomar M, Leon C, et al. Fungal colonization and/or infection in intensive care units. Multicenter study of 1562 patients. Med Clin (Barc) 2003; 121:161-166.
20. Yao Z, Liao W, Chen R, et al. Management of cryptococcosis in non-HIVrelated patients. Med Mycol 2005; 43:245-251.
21. Torres HA, Prieto VG, Raad II, et al. Proven pulmonary cryptococcosis due to capsule-deficient Cryptococcus neoformans does not differ clinically from proven pulmonary cryptococcosis due to capsule-intact Cr. neoformans. Mycoses 2005; 48:21-24. This article seems to challenge the previous view that the capsule should be considered as a virulence factor.
22. Vaideeswar P, Prasad S, Deshpande JR, et al. Invasive pulmonary aspergillosis: a study of 39 cases at autopsy. J Postgrad Med 2004; 50:21-26. Clinical presentations from patients with proven invasive pulmonary aspergillosis; no microbiological diagnosis was achieved before death.
23. Shaukat A, Bakri F, Young P, et al. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia 2005; 159:181-188.
24. Munyati SS, Dhoba T, Makanza ED, et al. Chronic cough in primary health care attendees, Harare. Zimbabwe: diagnosis and impact of HIV infection Clin Infect Dis 2005; 40:1818-1827.
25. Lass-Florl C, Gunsilius E, Gastl G, et al. Clinical evaluation of Aspergillus-PCR for detection of invasive aspergillosis in immunosuppressed patients. Mycoses 2005; 48 (suppl 1):12-17.
26. Musher B, Fredricks D, Leisenring W, et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004; 42:5517-5522.
27. Gulbahce HE, Pambuccian SE, Jessurun J, et al. Pulmonary nodular lesions in bone marrow transplant recipients: impact of histologic diagnosis on patient management and prognosis. Am J Clin Pathol 2004; 121:205-210.
28. Lindell RM, Hartman TE, Nadrous HF, et al. Pulmonary cryptococcosis: CT findings in immunocompetent patients. Radiology 2005; 236:326-331.
29. Franquet T, Muller NL, Lee KS, et al. Pulmonary candidiasis after hematopoietic stem cell transplantation: thin-section CT findings. Radiology 2005; 236:332-337.
30. Horger M, Einsele H, Schumacher U, et al. Invasive pulmonary aspergillosis: frequency and meaning of the "hypodense sign" on unenhanced CT. Br J Radiol 2005; 78:697-703. An article that illustrates the frequency and specificity of hypodense signs for invasive aspergillosis.
31. Sonnet S, Buitrago-Tellez CH, Tamm M, et al. Direct detection of angioinvasive pulmonary aspergillosis in immunosuppressed patients: preliminary results with high-resolution 16-MDCT angiography. Am J Roentgenol 2005; 184:746-751. A new diagnostic tool for angioinvasive pulmonary fungal infections.
32. Lehto JT, Koskinen PK, Anttila VJ, et al. Bronchoscopy in the diagnosis and surveillance of respiratory infections in lung and heart-lung transplant recipients. Transpl Int 2005; 18:562-571.
33. Nosari A, Anghilieri M, Carrafiello G, et al. Utility of percutaneous lung biopsy for diagnosing filamentous fungal infections in hematologic malignancies. Haematologica 2003; 88:1405-1409.
34. Zihlif M, Khanchandani G, Ahmed HP, et al. Surgical lung biopsy in patients with hematological malignancy or hematopoietic stem cell transplantation and unexplained pulmonary infiltrates: improved outcome with specific diagnosis. Am J Hematol 2005; 78:94-99.
35. Kleinberg M. Aspergillosis in the CLEAR outcomes trial: working toward a real-world clinical perspective. Med Mycol 2005; 43 (suppl 1):S289-S294. A CLEAR-type outcome study showed that overall response rate of ABLC to aspergillosis was 63%.
36. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-415.
37. Candoni A, Mestroni R, Damiani D, et al. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur J Haematol 2005; 75:227-233.
38. Matt P, Bernet F, Habicht J, et al. Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia. Chest 2004; 126:1783-1788.
39. Paganol L, Offidani M, Fianchi L, et al. Mucormycosis in hematologic patients. Haematologica 2004; 89:207-214. A 15-year retrospective study of 59 patients with hematologic malignancies with proven or probable mucormycosis, a large sample for the study of mucormycosis.
40. Pavie J, Lafaurie M, Lacroix C, et al. Successful treatment of pulmonary mucormycosis in an allogenic bone-marrow transplant recipient with combined medical and surgical therapy. Scand J Infect Dis 2004; 36:767-769.
41. Kim YT, Kang MC, Sung SW, et al. Good long-term outcomes after surgical treatment of simple and complex pulmonary aspergilloma. Ann Thorac Surg 2005; 79:294-298.
42. Gebitekin C, Sami Bayram A, Akin S. Complex pulmonary aspergilloma treated with single stage cavernostomy and myoplasty. Eur J Cardiothorac Surg 2005; 27:737-740.
43. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366:1413-1414. A multicenter, randomized, non-inferiority study showing that voriconazole was as effective as the regimen of amphotericin B followed by fluconazole in the treatment of candidaemia in non-neutropenic patients and with fewer toxic effects.
44. Kartsonis N, Killar J, Mixson L, et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother 2005; 49:3616-3623.
45. Arikan S, Sancak B, Hascelik G. In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital. Med Mycol 2005; 43:171-178.
46. Fanci R, Guidi S, Bonolis M, et al. Candida krusei fungemia in an unrelated allogeneic hematopoietic stem cell transplant patient successfully treated with Caspofungin. Bone Marrow Transpl 2005; 35:1215-1216.
47. DiNubile MJ, Hille D, Sable CA, et al. Invasive candidiasis in cancer patients: observations from a randomized clinical trial. J Infect 2005; 50:443-449. A multicenter, double-blind, randomized trial of caspofungin compared with conventional amphotericin B in the treatment of invasive candidiasis showed that 70% of caspofungin-treated and 56% of amphotericin B-treated cancer patients responded favorably.
48. Dummer JS, Lazariashvilli N, Barnes J, et al. A survey of anti-fungal management in lung transplantation. J Heart Lung Transpl 2004; 23:1376-1381. A multicenter uncontrolled analysis of antifungal prophylaxis used in lung transplantation in the USA.
49. Mattner F, Chaberny IF, Weissbrodt H, et al. Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole. Mycoses 2005; 48 (suppl 1):51-55.